Bioventix (BVXP) has announced its FY25 results to the end of June 2025 reflecting challenges associated with BVXP’s core antibody portfolio but also highly encouraging momentum in the company’s emerging Alzhemier’s portfolio. Group revenues of £13.1m were down c4% YoY from £13.6m and slightly below our estimates of £13.5m. This was largely driven by the evolving market landscape in China, which is facing pricing pressures and policies that encourage technology onshoring. Consequently, China rel ....
